coiaward2010

CML Clinical Trials Registry now lists 35 ongoing studies

Word Art 1

Patients wishing to participate in a clinical study often look for a central source of information where they can find easy-to-understand facts on ongoing trials. 

Official trial registries like clinicaltrials.gov or other trial registries are available but tend to be complex and difficult to use for patients.

To fill the need for a single source of information on CML studies in plain language, CML Advocates Network set up an unofficial online CML Trials Registryin 2013.

The database contains a brief description of ongoing CML trials initiated by academia (universities) or pharmaceutical companies.

Currently, 24 clinical studies are listed that are actively recruiting patients. Another 11 studies are still ongoing but no longer including new patients.

 

Lately, the following studies have been added to or updated in our CML Clinical Trials Registry

 

Trials after therapy failure or intolerance

 

1. OPUS = Optimizing Ponatinib Use [Italy]

 

2. OPTIC 2L = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

 

3. PF-114 Dose-finding Study in Ph+ CML Patients Resistant to 2nd Generation TKI or Presenting T315I Mutation [Russia]

 

4. CABL001X2101 = A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL

 

5. BYOND (B1871039) = Safety and Efficacy of Bosutinib in Ph+ CML Previously Treated with TKI

 

6. ABL001 versus bosutinib in CML-CP patients pretreated with ≥2 TKI [Asia, Australia, Europe, North America, South America]

 

7. BEST - Bosutinib in Elderly Chronic Myeloid Leukemia [Italy]

 

Therapy optimization trials

 

1. OPTIC = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

 

2. Pioglitazone and TKI [USA]

 

3. DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]

 

4. DECLINE = Imatinib versus nilotinib in CML in chronic phase

 

Other trials

 

1. PONDEROSA [Germany]

 

2. OMNI = Registry to evaluate vascular occlusive events with Iclusig [US]

 

The database is driven by patients without any sponsorship and updated by a medical writer in continuous dialogue with trial investigators and sponsors.

Patients should consult their doctor for personal advice and/or their scientific contact/study staff for the most up-to-date study information.

If you are aware of any study that is not yet listed in our Clinical Trials Register, please let us know by filling out this form.

We would like to thank everyone for sharing information on new studies or informing us about any changes in ongoing studies. Together we can improve access of CML patients to clinical trials worldwide!

You can access the complete CML Clinical Trials Registry HERE.


 
   
 

Please donate!

Please donate!

LogIn

Tweet Feed

cmlnet
CML Advocates Network participating at ESH-SWG 2018 Meeting. We offered the #CML #patient perspective, issues and c… twitter.com/i/web/status/9…

Tuesday, 20 February 2018

cmlnet
Welcome, Celebrando la Vida, Bolivia! Now 117 #patient organisations from 87 countries in the #CML Advocates Networ… twitter.com/i/web/status/9…

Monday, 19 February 2018